Eli Lilly and (NYSE: LLY) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Eli Lilly and to similar businesses based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, valuation and dividends.


Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Eli Lilly and pays out 98.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 65.7% of their earnings in the form of a dividend. Eli Lilly and has raised its dividend for 2 consecutive years. Eli Lilly and lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.

Volatility & Risk

Eli Lilly and has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Eli Lilly and’s peers have a beta of 37.04, indicating that their average stock price is 3,604% more volatile than the S&P 500.

Earnings & Valuation

This table compares Eli Lilly and and its peers top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Eli Lilly and $21.22 billion $2.74 billion 39.58
Eli Lilly and Competitors $8.17 billion $1.09 billion 121.42

Eli Lilly and has higher revenue and earnings than its peers. Eli Lilly and is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

76.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Eli Lilly and shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Eli Lilly and and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eli Lilly and 9.90% 30.27% 10.82%
Eli Lilly and Competitors -2,399.97% -68.06% -7.34%

Analyst Ratings

This is a breakdown of current recommendations for Eli Lilly and and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and 1 6 10 0 2.53
Eli Lilly and Competitors 863 3776 6743 178 2.54

Eli Lilly and currently has a consensus price target of $91.19, indicating a potential upside of 9.19%. As a group, “Pharmaceuticals” companies have a potential upside of 22.29%. Given Eli Lilly and’s peers stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and has less favorable growth aspects than its peers.


Eli Lilly and peers beat Eli Lilly and on 8 of the 15 factors compared.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.